An experimental drug tested on lab animals has shown remarkable success in tackling two viruses, including a close cousin to a feared bioterror pathogen, a study published on yesterday said.
The drug, bavituximab, takes a novel tack in confronting viruses, which are notorious for mutations that evade or resist conventional pharmaceutical molecules.
Instead of confronting the intruder head-on, bavituximab waits until the virus has infected the cell.
At that point, a fatty molecule called phosphatidylserine, which is normally positioned on the cell wall’s internal surface, flips to the outside of the cell.
Bavituximab then latches onto the phosphatidylserine, sending a red flag to the body’s immune system to dispatch white blood cells to destroy the infected cell.
In a study in Nature Medicine, published by the London-based Nature group, bavituximab was put through its paces among guinea pigs infected with Pichinde virus — a close relative of the Lassa fever virus, considered a potential bioterror weapon by the Pentagon.
Animals that had not been inoculated with bavituximab were all killed; those who had received the injection had a 50 percent survival rate.
By giving the bavituximab group an additional injection with a standard anti-virus drug called ribavirin, the survival rate rose to 63 percent.
The drug also provided 100 percent protection amongst mice exposed to a virus called cytomegalovirus (CMV), whereas only 25 percent of untreated animals survived.
Co-author Philip Thorpe, a professor of pharmacology at UT Southwestern Medical Center in Texas, said the findings were exciting, for they raised the prospect of a “completely new class” of anti-viral drugs that may also sidestep the problem of mutation.
“By targeting a property of the host cell rather than the virus itself, anti-PS [phosphatidylserine] antibodies have the potential to treat a range of viral infections,” he said in a press release.
“They should be less susceptible to the viral mutations that contribute to the development of drug resistance,” Thorpe said.
Bavituximab, a monoclonal antibody, is currently in clinical trials by Peregrine Pharmaceuticals Inc. of California to treat patients with hepatitis C.
Previous research has shown that phosphatidylserine-flipping occurs in cells infected with influenza, the herpes simplex virus, viruses in the families of the smallpox and rabies viruses as well as HIV, UT Southwestern Medical Center said.
The pitch is a classic: A young celebrity with no climbing experience spends a year in hard training and scales Mount Everest, succeeding against some — if not all — odds. French YouTuber Ines Benazzouz, known as Inoxtag, brought the story to life with a two-hour-plus documentary about his year preparing for the ultimate challenge. The film, titled Kaizen, proved a smash hit on its release last weekend. Young fans queued around the block to get into a preview screening in Paris, with Inoxtag’s management on Monday saying the film had smashed the box office record for a special cinema
CRITICISM: ‘One has to choose the lesser of two evils,’ Pope Francis said, as he criticized Trump’s anti-immigrant policies and Harris’ pro-choice position Pope Francis on Friday accused both former US president Donald Trump and US Vice President Kamala Harris of being “against life” as he returned to Rome from a 12-day tour of the Asia-Pacific region. The 87-year-old pontiff’s comments on the US presidential hopefuls came as he defied health concerns to connect with believers from the jungle of Papua New Guinea to the skyscrapers of Singapore. It was Francis’ longest trip in duration and distance since becoming head of the world’s nearly 1.4 billion Roman Catholics more than 11 years ago. Despite the marathon visit, he held a long and spirited
‘DISAPPEARED COMPLETELY’: The melting of thousands of glaciers is a major threat to people in the landlocked region that already suffers from a water shortage Near a wooden hut high up in the Kyrgyz mountains, scientist Gulbara Omorova walked to a pile of gray rocks, reminiscing how the same spot was a glacier just a few years ago. At an altitude of 4,000m, the 35-year-old researcher is surrounded by the giant peaks of the towering Tian Shan range that also stretches into China, Kazakhstan and Uzbekistan. The area is home to thousands of glaciers that are melting at an alarming rate in Central Asia, already hard-hit by climate change. A glaciologist, Omarova is recording that process — worried about the future. She hiked six hours to get to
The number of people in Japan aged 100 or older has hit a record high of more than 95,000, almost 90 percent of whom are women, government data showed yesterday. The figures further highlight the slow-burning demographic crisis gripping the world’s fourth-biggest economy as its population ages and shrinks. As of Sept. 1, Japan had 95,119 centenarians, up 2,980 year-on-year, with 83,958 of them women and 11,161 men, the Japanese Ministry of Health said in a statement. On Sunday, separate government data showed that the number of over-65s has hit a record high of 36.25 million, accounting for 29.3 percent of